GC Genome Corporation (KOSDAQ:340450)
South Korea · Delayed Price · Currency is KRW 7,400.00
-500.00 (-6.33%)
At close: Mar 23, 2026
GC Genome Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 4,044 | -1,257 | -550.1 | -3,763 | 293.2 |
Depreciation & Amortization | 2,867 | 3,219 | 3,541 | 2,807 | 2,057 |
Loss (Gain) From Sale of Assets | 139.05 | -1.37 | -1.57 | 44.89 | 13.83 |
Asset Writedown & Restructuring Costs | - | 1,125 | - | - | - |
Loss (Gain) From Sale of Investments | -1,828 | - | - | - | - |
Loss (Gain) on Equity Investments | -553.47 | - | - | 2.93 | - |
Stock-Based Compensation | 586 | - | - | - | - |
Provision & Write-off of Bad Debts | 84.68 | 7.42 | -4.25 | -6.17 | 29.55 |
Other Operating Activities | -60.97 | -176.66 | 1,702 | 1,897 | -1,225 |
Change in Accounts Receivable | -1,642 | -1,133 | -83.41 | -517.76 | -2,128 |
Change in Inventory | -802.12 | -97.71 | 30.87 | -617.92 | -610.08 |
Change in Accounts Payable | - | -851.58 | -459.75 | 17.83 | 1,293 |
Change in Other Net Operating Assets | -1,537 | -457.3 | -834.42 | -1,474 | 207.98 |
Operating Cash Flow | 1,297 | 377.99 | 3,340 | -1,610 | -67.7 |
Operating Cash Flow Growth | 243.12% | -88.69% | - | - | - |
Capital Expenditures | -311.39 | -328.59 | -7,406 | -4,029 | -2,868 |
Sale of Property, Plant & Equipment | 5.86 | - | - | 813.98 | - |
Sale (Purchase) of Intangibles | -42.99 | -87.11 | -49.42 | -40.7 | -169.27 |
Investment in Securities | -11,948 | 3,819 | -4,965 | 8,950 | 5,236 |
Other Investing Activities | -183.7 | -275.52 | -55.46 | -517.26 | -302.52 |
Investing Cash Flow | -12,480 | 3,128 | -12,476 | 5,177 | 1,897 |
Long-Term Debt Repaid | -664.11 | -615.54 | -859.19 | -671.84 | -490.16 |
Total Debt Repaid | -664.11 | -615.54 | -859.19 | -671.84 | -490.16 |
Net Debt Issued (Repaid) | -664.11 | -615.54 | -859.19 | -671.84 | -490.16 |
Issuance of Common Stock | 40,437 | - | - | - | - |
Financing Cash Flow | 39,773 | -615.54 | -859.19 | -671.84 | -490.16 |
Foreign Exchange Rate Adjustments | 0.04 | 0.01 | -5.41 | -0.99 | - |
Miscellaneous Cash Flow Adjustments | - | - | - | - | -0 |
Net Cash Flow | 28,590 | 2,891 | -10,000 | 2,894 | 1,339 |
Free Cash Flow | 985.56 | 49.4 | -4,065 | -5,639 | -2,935 |
Free Cash Flow Growth | 1895.10% | - | - | - | - |
Free Cash Flow Margin | 3.13% | 0.19% | -14.90% | -23.39% | -15.87% |
Free Cash Flow Per Share | 45.08 | 2.71 | -221.71 | -349.17 | -183.51 |
Cash Interest Paid | 185.6 | 210.9 | 173.16 | 116.04 | - |
Cash Income Tax Paid | 58.45 | -2.53 | -3.1 | -54.92 | 31.28 |
Levered Free Cash Flow | -1,055 | -3,001 | -7,596 | -933.3 | -3,846 |
Unlevered Free Cash Flow | -931.72 | -2,401 | -7,021 | 126.36 | -2,919 |
Change in Working Capital | -3,981 | -2,539 | -1,347 | -2,592 | -1,236 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.